COMPANY PROFILE

Phagelux

Explore full profile

Phagelux is a China-based company that utilizes phages to solve bacterial problems in multiple fields

Huangpu, ChinaFounded 2013Biotech & Life Sciences

Valuation $50–100M Last recorded · 2015

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Phagelux

Phagelux AgriHealth, Inc. is a global biotechnology company that focuses on sustainable agriculture by developing and manufacturing safe biological alternatives to chemicals and antibiotics. These alternatives are designed to improve crop yields and reduce the cost impacts of bacterial diseases in crop science, animal health, and food safety. The company operates in multiple markets worldwide, with manufacturing facilities in the United States and China, and subsidiaries in the United States, China, and Europe. Phagelux AgriHealth serves farmers and agricultural businesses looking for eco-friendly and effective solutions to manage bacterial diseases. The company's business model revolves around the sale of its proprietary products, which are based on a novel bacterial control platform using bacteriophages. Revenue is generated through direct sales and partnerships with agricultural distributors.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2013
Headquarters: Huangpu, China
Employees: 11
Open positions: None listed
Dealroom signal: 36.7/100
Industry: Health, Food
Sub-industry: BioTechnology, AgriTech
Sector: Biotech & Life Sciences, Biotechnology, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Apr 2025	$0	—	Anhui Provincial State-owned Assets Supervision and Administration Commission	↗
OtherOther financing	Mar 2022	$0	—	Shuimu Chunjin Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Phagelux website traffic

Latest recorded traffic for Phagelux is 570 monthly website visits, up 200% over the last three months. Phagelux's team declined 8.3% over the past year.

Latest monthly visits570 3-month web change+200% 1-year team growth-8.3%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
GAGLX AnalytixBringing personalized medicine to your health care	Copenhagen, Denmark	Operational
FLFlomicsRNA liquid biopsy for early multi-cancer detection	Barcelona, Spain	Operational
AXAxonicsCompany developing novel implantable neuromodulation	Irvine, United States	Acquired
BLBluedotStudies how infectious diseases disperse worldwide through analysis of big data	Toronto, Canada	Operational
IMiCellate MedicalDevelops products in the areas of cancer diagnosis, based on detection and analyses of circulating tumour cells (CTC), circulating tumour DNA (ctDNA) and germline DNA	Solna kommun, Sweden	Operational
IMImaginAbClinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins	Inglewood, United States	Acquired
ATAudentes TherapeuticsAudentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.	San Francisco, United States	Acquired